SCHEMBL4947706

SCHEMBL4947706

CNc1cc(Nc2ccc(OCCN3CCCC3)c(F)c2)ncn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 2/20 0.50
LTA4H P09960 1/20 0.50
EGFR P00533 4/20 0.48
EHMT2 Q96KQ7 1/20 0.47
EHMT1 Q9H9B1 1/20 0.47
KDR P35968 6/20 0.46
INSR P06213 1/20 0.45
EPHA2 P29317 2/20 0.43
EPHB4 P54760 2/20 0.43
TNK2 Q07912 2/20 0.42
GALR2 O43603 1/20 0.42
GALR1 P47211 1/20 0.42
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
LCK P06239 1/20 0.42
BTK Q06187 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
FGFR1 P11362 1/20 0.42
FLT1 P17948 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL374814 0.83 CYP3A4 (0.53) AXLLTA4HKDREPHB4CYP3A4
SCHEMBL4949923 0.78 LTA4H (0.49) LTA4HKDRESR1ESR2SMN1; SMN2
SCHEMBL374753 0.75 SRC (0.50) AXLLTA4HEGFRKDRFGFR1
SCHEMBL24304284 0.74 BRD4 (0.63) AXLEGFRKDRINSREPHA2
SCHEMBL4947033 0.73 ABL1 (0.59) LTA4HSMN1; SMN2CYP3A4
SCHEMBL374259 0.72 CYP3A4 (0.51) LTA4HEGFRCYP3A4FGFR3
SCHEMBL13855799 0.72 SMN1; SMN2 (0.71) LTA4HESR1ESR2SMN1; SMN2CYP3A4
SCHEMBL4489929 0.72 AXL (0.57) AXLLTA4HEGFRKDRINSR
SCHEMBL30367433 0.72 EHMT2 (0.61) EGFREHMT2EHMT1KDRBTK
SCHEMBL19476898 0.72 EHMT2 (0.61) EGFREHMT2EHMT1KDRBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1976847-B1 PYRIMIDINYL ARYL UREA DERIVATIVES BEING FGF INHIBITORS NOVARTIS AG (CH) 2015-06-17 EP disclosed
US-8759517-B2 Pyrirnidinyl aryl urea derivatives being FGF inhibitors NOVARTIS AG (CH) 2014-06-24 US disclosed
US-20130030171-A1 Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors NOVARTIS AG (CH) 2013-01-31 US disclosed
US-8293746-B2 Pyrimidinyl aryl urea derivatives being FGF inhibitors NOVARTIS AG (CH) 2012-10-23 US disclosed
US-20080312248-A1 Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors NOVARTIS AG 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312248-A1 Pyrimidinyl Aryl Urea Derivatives Being Fgf Inhibitors FGFR1, FGF1, FGF2 AXL 22/4885LTA4H 3869/4885EGFR 17/4885
US-20130030171-A1 Pyrimidinyl Aryl Urea Derivatives being FGF Inhibitors FGFR1, FGF1, FGF2 AXL 22/4885LTA4H 3869/4885EGFR 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.